Review of screening guidelines for non-AIDS-defining malignancies: Evolving issues in the era of highly active antiretroviral therapy

AIDS Reviews

Volumn 14, Issue 1, 2012, Pages 3-16

  Zachary, Tyerman ^a   Aboulafia, David M ^a,b  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer screening; HAART; Highly active antiretroviral therapy era; HIV AIDS; Non aids defining malignancies

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; WART VIRUS VACCINE;

ANILINGUS; ANUS CANCER; BREAST CANCER; BREAST EXAMINATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; COLPOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; FOLLOW UP; HEALTH CARE COST; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE HOMOSEXUAL; MAMMOGRAPHY; MORBIDITY; MORTALITY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POPULATION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA OF THE ANUS; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VISUAL SYSTEM EXAMINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HOMOSEXUALITY, MALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROSTATIC NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84858973633     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Jones J, Hanson D, Dworkin M, et al. Surveillance for AIDS-defining opportunistic illnesses 1992-1997. Morb Mortal Wkly Rep. 1999;48:1-22.
2. Chang Y, Cesarman E, Pessin M, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-9.
3. Epstein, M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1965;121:761-70.
4. Zur Hausen H. Papillomaviruses in human cancer. Appl Pathol. 1987;5:19-24. (Pubitemid 17110738)
5. Grulich A, van Leeuwen M, Falster M, Vajdic C. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67. (Pubitemid 47017468)
6. Sackoff J, Hanna D, Pfeiffer M, Torian L. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406. (Pubitemid 46768570)
7. Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. (Pubitemid 44306484)
8. Shiels M, Cole S, Kirk G, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immun Defic Syndr. 2009;52:611-22.
9. Shiels M, Pfeiffer R, Gail M, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-62.
10. Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral era. Curr HIV/AIDS Rep. 2008;5:140-9.
11. Clifford G, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-32. (Pubitemid 40528605)
12. Biggar R, Chaturvedi A, Goedert J, Engels E; The HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962-72. (Pubitemid 47073502)
13. Hessol N, Seaberg E, Preston-Martin S, et al; WIHS Collaborative Study Group. Cancer risk among participants of the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2004;36:978-85. (Pubitemid 38949847)
14. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine M. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS. 1998;12:1459-64. (Pubitemid 28369645)
15. Schuman P, Ohmit S, Klein R, et al; HIV Epidemiology Research Study Group. Longitudinal study of cervical squamous intraepithelial lesions in human-immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003;188:128-36. (Pubitemid 36829752)
16. Gingelmaier A, Grubert T, Kaestner R, et al. High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1 infected women. Anticancer Res. 2007;27:1795-8. (Pubitemid 46954678)
17. Lehtovirta P, Paavonen J, Heikinheimo O. Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women. Int J STD AIDS. 2008;19:37-41. (Pubitemid 351738841)
18. Bower M, Mazhar D, Stebbing J. Should cervical cancer be an acquired immunodeficiency syndrome-defining cancer? J Clin Oncol. 2006;24:2417-19. (Pubitemid 46630616)
19. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8:1-12.
20. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104:1505-11. (Pubitemid 41356166)
21. Barbaro G, Barbarini G. HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Reports. 2007;17:1121-6.
22. Ho G, Bierman R, Beardsley L, Chang C, Burk R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-8. (Pubitemid 28135669)
23. Grinsztein B, Veloso V, Levi J, et al. Factors associated with increased prevalence of human papilloma virus in a cohort of HIV-infected Brazilian women. Int J Infect Dis. 2009;13:72-80.
24. Palefsky J, Holly E, Hogeboom C, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr. 1998;17:314-19.
25. Nguyen M, Farrell K, and Gunthel J. Non-AIDS-defining malignancies in patients with HIV in the HAART era. Curr Infect Dis Rep. 2010;12:46-55.
26. Stebbing J, Duru O, Bower M. Non-AIDS-defining cancers. Curr Opin Infect Dis. 2009;22:7-10.
27. El-Sadr W, Lundgren J, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96. (Pubitemid 44837777)
28. Silverberg M, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART Study. AIDS. 2007;21:1957-63. (Pubitemid 47329772)
29. Lichtenstein K. Antiretroviral treatment interruptions and risk of non-opportunistic diseases. Curr HIV/AIDS Rep. 2009;6:77-82.
30. World Health Organization. Antiretroviral therapy for HIV-infection and adolescents: recommendations for a public health approach. WHO Press; 2010 (cited 2011 Jun 8). Available from: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf
31. Braithwaite R, Justice A, Change C, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118:890-8. (Pubitemid 41097468)
32. Justice A, Lasky E, McGinnis K, et al. Medical disease and alcohol use among veterans with human immunodeficiency virus infection: a comparison of disease measurement strategies. Med Care. 2006;44(Suppl 2):S52-60. (Pubitemid 44284258)
33. Bräu N, Fox R, Xiao P, et al; The North American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527-37. (Pubitemid 47334759)
34. Staples C, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29:150-4. (Pubitemid 29336817)
35. D'Jaen G, Pantanowitz L, Bower M, et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer. 2010;11:396-404.
36. Wilson J, Junger G. Principles and practice of screening for disease. Public Health Papers. 1968;4:26-39.
37. Frisch M, Biggar R, Goedert J. Human papilloma virus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500-10.
38. Rellition M, Darby D, Burk T, Berkland M, Longfield R. Rapidly progressive cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol. 1990;36:435-8. (Pubitemid 20116926)
39. Castro K, Ward J, Slutsker L, Buehler J, Jaffe H, Berkelman R; National Center for Infectious Diseases Division of HIV/AIDS. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep. 1992;41:1-19.
40. Denny L, Boa R, Williamson A, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol. 2008;111:1380-7.
41. Soncini E, Zoncada A, Condemi V, Antoni A, Bocchialini E, Soregotti P. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed. 2007;78:36-40.
42. Heard I, Palefsky J, Kazatchkine M. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther. 2004;9:13-22. (Pubitemid 38313943)
43. Ahdieh-Grant L, Li R, Levine A, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2004;96:1070-6. (Pubitemid 39172408)
44. American Academy of Family Physicians. 2011. (Updated 2003; cited 2011 Jun 7). A-E: Recommendations for Clinical Preventive Services (about screen 7). Available from: http://www.aafp.org/online/en/home/clinical/exam/a-e.html.
45. Barclay, Laurie. ACOG issues revised cervical cancer screening guidelines. Medscape Medical News; 2009 (cited 2011 Jun 10). Available from: http://www.medscape.com/viewarticle/712840.
46. American Cancer Society. 2011 (updated 2010 Dec 23; cited 2011 Jun 9). Cervical cancer; (screens 11-17) Available from: http://www.cancer.org/acs/ groups/cid/documents/webcontent/003167-pdf.pdf.
47. U.S. Preventive Services Task Force; (updated 2003 Jan; cited 2011 Jun 6). Screening for cervical cancer; (about 1 screen). Available from: http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm.
48. Centers for Disease Control (updated 2011 Jan 28; cited 2011 Jun 10). Cervical cancer screening for women who attend STD clinics or have a history of STDs; (about 5 screens). Available at: http://www.cdc.gov/std/treatment/2010/cc- screening.htm.
49. Engels E, Biggar R, Hall H, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187-94. (Pubitemid 351705208)
50. Ellerbrock T, Chiasson M, Bush T, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-7. (Pubitemid 30112217)
51. Anderson J, Paramsothy P, Heilig C, Jamieson D, Shah K, Duerr A; HIV Epidemiology Research Study Group. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis. 2006;42:562-8. (Pubitemid 43202531)
52. Maiman M, Fruchter R, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol. 1998;68:233-9. (Pubitemid 28183491)
53. Wright T, Massad L, Dunton C, et al; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for managing of women with abnormal cervical screening tests. Am J Obstet Gynecol. 2007;197:346-55. (Pubitemid 47464164)
54. Kaplan J, Benson C, Holmes K, Brooks J, Pau A, Masur H; Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-Infected adults and adolescents. MMWR Recomm Rep. 2009;58:70-1.
55. New York State Department of Health AIDS Institute. Promoting GYN care for HIV-infected women: best practices for New York State. 2000 (cited 2011 Jun 11). Available from: http://www.ihi.org/IHI/Topics/HIVAIDS/HIVDisease-General/ Tools/PromotingGynecologicalGYNCareforHIVInfectedWomen.htm.
56. U.S. Public Health Service and the Infectious Diseases Society of America Prevention of Infections Working Group. Guidelines for the prevention of opportunistic infections among HIV-infected persons. National Center for HIV, STD, and TB Prevention; 2002 (cited 2011 Jun 11). Available from: http://aidsinfo.nih.gov/contentfiles/OIpreventionGL.
57. Goldie S, Weinstein M, Kuntz K, Freedberg K. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med. 1999;130:97-107. (Pubitemid 29045357)
58. Massad L, Evans C, Strickler H, et al. Outcome after negative colposcopy among human immunodeficiency virus-infected women with borderline cytologic abnormalities. Obstet Gynecol. 2005;106:525-32. (Pubitemid 41208784)
59. Swierczynski S, Lewis-Chambers S, Anderson J, Keller J, Hinkle D, Ali S. Impact of liquid-based gynecologic cytology on an HIV-positive population. Acta Cytol. 2004;48:165-72. (Pubitemid 38381101)
60. Boardman L, Cotter K, Raker C, Cu-Uvin S. Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology. Obstet Gynecol. 2008;112:238-43.
61. Kitchener H, Nelson L, Adams J, et al. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer. 2007;121:2484-91. (Pubitemid 350022418)
62. Womack S, Chirenje Z, Gaffikin L, et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer. 2000;85:206-10. (Pubitemid 30023069)
63. Kuhn L, Wang C, Wei- Tsai W, Wright T, Denny L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS. 2010;24:255361.
64. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2008;17:253645.
65. Johnson Z, Madeleine M, Newcomer L, Schwartz S, Daling J. Anal cancer incidence and survival, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281-8. (Pubitemid 38890830)
66. Margolies L, Goeren B. Anal cancer, HIV, and gay/bisexual men. New York: Gay Men's Health Crisis; 2009 (cited 2011 Jun 12). Available from: www.gmhc.org/files/editor/file/ti-0909.pdf.
67. Patel P, Hanson D, Sullivan P, et al.; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence and types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-36. (Pubitemid 351717418)
68. Etienny I, Vuong S, Daniel F, et al. Prevalence of anal cytological abnormalities in a French referral population: a prospective study with special emphasis on HIV, HPV, and smoking. Dis Colon Rectum. 2008;51:67-72.
69. Clark M, Hartley A, Geh J. Cancer of the anal canal. Lancet Oncol. 2004;5:149-57. (Pubitemid 38262846)
70. Piketty C, Darragh T, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138:453-9.
71. Crum-Cianflone N, Hullsiek K, Marconi V, et al.; Infectious Disease Clinical Research Program HIV Working Group. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010;24:535-43.
72. Zanet E, Berreta M, Martellotta F, et al. Anal cancer: focus on HIVpositive patients in the HAART era. Curr HIV Res. 2011;9:70-81.
73. D'Souza G, Wiley D, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2008;48:491-9.
74. Abramowitz L, Benabderrahmane D, Ravaud P, et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS. 2007;21:1457-65. (Pubitemid 46988006)
75. U.S. Food and Drug Administration. Gardasil approved to prevent anal cancer. United States Department of Health and Human Services; 2010 (cited 2011 Jun 11). Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm237941.htm.
76. Giuliano A, Palefsky J, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Eng J Med. 2011;5:364-401.
77. Wilkin T, Lee J, Lensing S, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1 infected men. J Infect Dis. 2010;202:1246-53.
78. Bower M, Collins S, Cottrill C, et al.; AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008;9:336-88. (Pubitemid 352015641)
79. Phillips A, Justman J. Screening HIV-infected patients for non-AIDSdefining malignancies. Curr HIV/AIDS Rep. 2009;6:83-92.
80. Chiao E, Giordano T, Palefsky J, Tyring S, El Serag H. Screening HIVinfected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43:223-33.
81. Cranston R, Hart S, Gornbein J, Hirschowitz S, Cortina G, Moe A. The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men. Int J STD AIDS. 2007;18:77-80.
82. Arain S, Walts A, Thomas P, Bose S. The anal Pap smear: cytomorphology of squamous intraepithelial lesions. Cytojournal. 2005;2:4.
83. National AIDS Treatment Advocacy Project. NYS Guidelines recommendations on anal pap smears. 2010 (cited 2011 Jun 12). Available from: http://www.natap.org/2010/HIV/032510-01.htm.
84. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess. 2010;53:iii-iv,ix-x,1-101.
85. Highleyman L. Human Papillomavirus. BETA. 2007:35-9.
86. American Cancer Society. 2011 (updated 2011 Feb 9; cited 2011 Jun 6). Breast cancer; (screens 9-19) Available from: http://www.cancer.org/acs/groups/ cid/documents/webcontent/003090-pdf.pdf.
87. Palmer J, Boggs D, Adams-Campbell L, Rosenberg L. Family history of cancer and risk of breast cancer in the Black Women's Health study. Cancer Causes Control. 2009;20:1733-7.
88. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606-16. (Pubitemid 34498648)
89. Colditz G, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000;152:950-64.
90. Amir H, Kaaya E, Kwesigabo G, Kiitinya J. Breast cancer before and during the AIDS epidemic in women and men: a study of Tanzanian Cancer Registry Data 1968 to 1996. J Natl Med Assoc. 2000;92:301-5.
91. Intra M, Gentillini O, Brenelli F, Chagas E, Veronesi U, Sandri M. Breast cancer among HIV-infected patients: The experience of the European Institute of Oncology. J Surg Oncol. 2005;91:141-2. (Pubitemid 41077057)
92. Stuart T, Tsai S, Grayson H, Henderson T, Opelz G. Incidence of de novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995;346:796-8.
93. Birkeland S, Storm H, Lamm L, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60:183-9.
94. Frisch M, Biggar R, Engels E, Goedert J; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736-45. (Pubitemid 32259908)
95. Latif N, Rana F, Guthrie T. Breast cancer and HIV in the era of highly active antiretroviral therapy: two case reports and review of the literature. Breast J. 2011;17:87-92.
96. Hessol N, Napolitano L, Smith D, et al. HIV tropism and decreased risk of breast cancer. PLoS ONE. 2010;5:e14349.
97. Pantanowitz L, Schecht H, Dezube B. The growing problem of non-AIDS defining malignancies in HIV. Curr Opin Oncol. 2006;18:469-78. (Pubitemid 44199843)
98. Olowole S, Ali A, Shaface Z, DePaz H. Breast cancer in women with HIV/AIDS: report of five cases with a review of literature. J Surg Oncol. 2005;89:23-7. (Pubitemid 40075965)
99. Voutsadakis I, Silverman L. Breast cancer in HIV-positive women: a report of four cases with a review of literature. Cancer Invest 2002;20:452-7. (Pubitemid 34686340)
100. Sullivan, MG. Change in mammography guidelines may adversely affect young minority women. Elsevier BV; 2011 (cited 2011 Jun 12). Available from: http://www.medconnect.com.sg/tabid/92/s3/Oncology/p12/Breast-Cancer/ct1/c41047/ Change-in-Mammography-Guidelines-May-Adversely- Affect-Young-Minority-Women-/ Default.aspx.
101. AAFP News Now. Updated AAFP breast cancer screening recommendations stress communication. American Academy of Family Physicians; 2010 (cited 2011 Jun 6). Available from: http://www.aafp.org/online/en/home/publications/news/ news-now/clinical-care-research/20100115aafp-brca-recs.html.
102. The American Congress of Obstetricians and Gynecologists. Lippincott Williams & Wilkins. 2011(updated 2009 Nov 16; cited 2011 Jun 6). Interpreting the U.S. Preventive Services Task Force breast cancer screening recommendations for the general population; (about 2 screens). Available from: http://www.acog.org/from-home/Misc/uspstfinterpretation.cfm.
103. American Cancer Society. 2011 (updated 2010 Sep 17; cited 2011 Jun 12). American Cancer Society recommendations for early breast cancer detection; (about 7 screens). Available from: http://www.cancer.org/Cancer/BreastCancer/ DetailedGuide/breast-cancer-detection.
104. U.S. Preventive Services Task Force (updated 2009 Nov; cited 2011 Jun 12). Screening for breast cancer; (about 1 screen). Available from: http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm.
105. Saslow D, Boetes C, Burke W, et al.; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. (Pubitemid 46535708)
106. Wingerson L. Breast cancer screening in 2025: Mammography, MRI, or more? London: UBM Medica; 2011 (cited 2011 Jun 12). Available from: http://www.diagnosticimaging.com/conferencereports/ecr2011/content/article/ 113619/1816244.
107. Seth A, Moore R, Gebo K. Provision of general and HIV-specific health maintenance in middle aged adults and older patients in an urban HIV clinic. AIDS Patient Care STDS. 2006;20:318-25. (Pubitemid 43804809)
108. Preston-Martin S, Kirstein L, Pogoda J, et al. Use of mammographic screening by HIV-infected women in the Women's Interagency HIV Study (WIHS). Prev Med. 2002;34:386-92. (Pubitemid 34969599)
109. Brawley O. Prostate cancer screening. Principl Prac Oncol. 2010;24:1.
110. American Cancer Society. 2011 (updated 2011 May 22; cited 2011 Jun 6). Prostate cancer; (screens 4-7). Available from: http://www.cancer.org/acs/ groups/cid/documents/webcontent/003134-pdf.pdf.
111. Hessol N, Pipkin S, Schwarcz S, Cress R, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007;165:1143-53. (Pubitemid 47233717)
112. Shiels M, Goedert J, Moore R, Platz E, Engles E. Reduced risk of prostate cancer in U.S. men with AIDS. Cancer Epidemiol Biomarkers Prev. 2010;19:2910-15.
113. Biggar R, Kirby K, Atkinson J, McNeel T, Engels E.; the AIDS Cancer Match Study Group. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr. 2004;36:861-8. (Pubitemid 38859353)
114. Levinson A, Nagler E, Lowe F. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology. 2005;65:91-4. (Pubitemid 40169612)
115. Illic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: an updated Cochrane Database systematic rev. BJU Int. 2011;107:882-91.
116. Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ. 2011;342:d1539.
117. Schröder F, Hugosson J, Roobol M, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
118. Mulcahy N. 'Excessive' PSA screening in elderly men. Medscape Medical News; 2011 (cited 2011 Jun 12). Available from: http://www.medscape.com/ viewarticle/739842.
119. American Urological Association. American Urological Society Education and Research, Inc; 2009 (cited 2011 Jun 13) Prostate-specific antigen best practice statement: 2009 Update. Available from: http://www.auanet.org/content/ guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf.
120. American Cancer Society. 2011 (updated 2011 May 22; cited 2011 Jun 13). American Cancer Society recommendations for early detection of prostate cancer; (about 5 screens). Available from: http://www.cancer.org/Cancer/ProstateCancer/ DetailedGuide/prostate-cancer-detection.
121. U.S. Preventive Services Task Force (updated 2008 Aug; cited 2011 Jun 13). Screening for prostate cancer; (about 1 screen). Available from: http://www.uspreventiveservicestaskforce.org/uspstf/uspsprca.htm.
122. Crum N, Spencer C, Amling C. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer. 2004;101:294-9. (Pubitemid 38890832)
123. Vianna L, Lo Y, Klein R. Serum prostate-specific antigen levels in older men with or at risk for HIV. HIV Med. 2006;7:471-6. (Pubitemid 44269815)
124. American Cancer Society. 2011 (updated 2010 Dec 16; cited 2011 Jun 13). Lung cancer; (screens 6-12). Available from: http://www.cancer.org/acs/groups/ cid/documents/webcontent/003115-pdf.pdf.
125. Lavol?A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J. Lung cancer, a new challenge in the HIV-infected population. Lung Cancer. 2006;51:1-11.
126. Spano J, Massiani M, Bentata M, et al. Lung cancer in patients with HIV infection and review of the literature. Med Oncol. 2004;21:109-15. (Pubitemid 39108000)
127. Cadranel J, Garfield D, Lavol?A, Wislez M, Milleron B, Mayaud C. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax. 2006;61:1000-8. (Pubitemid 44787172)
128. Hakimian R, Fang H, Thomas L, Edelman M. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol. 2007;2:268-72. (Pubitemid 47181707)
129. Giardano T, Kramer I. Does HIV infection independently increase the incidence of lung cancer? Clin Infect Dis. 2005;40:490-1.
130. Silverberg M, Chao C, Leyden W, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337-45.
131. Engels E, Pfeiffer R, Goedert J, et al.; HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-54. (Pubitemid 44162407)
132. Kirk G, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infec Dis. 2007;45:103-10. (Pubitemid 46984625)
133. Brock M, Hooker C, Engels E, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006;43:47-55. (Pubitemid 44306487)
134. Pastorino U. Lung cancer screening. Br J Cancer. 2010;102:1681-6.
135. Marcus P, Bergstralh E, Zweig M, Harris A, Offord K, Fontana R. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst. 2006;98:74856.
136. NCI Division of Cancer Prevention. The National Cancer Institute; 2011 (cited 2011 Jun 6). Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; (about 1 screen). Available from: http://prevention.cancer.gov/plco.
137. Henschke C, McCauley D, Yankelevitz D, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354:99-105. (Pubitemid 29313143)
138. National Cancer Institute. Lung cancer trial results show mortality benefit with low-dose CT. National Institutes of Health; 2010 (cited 2011 Jun 14). Available from: http://www.cancer.gov/newscenter/pressreleases/2010/ NLSTresultsRelease.
139. Kuehn B. Lung cancer screening. JAMA. 2010;304:2687.
140. Vidrine D, Arduino R, Lazev A, Gritz E. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS. 2006;20:253-60.
141. Ingersoll K, Cropsey K, Heckman C. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009;13:545-54.
142. American Cancer Society. 2011 (updated 2011 Mar 2; cited 2011 Jun 6). Colorectal cancer; (screens 4-9). Available from: http://www.cancer.org/acs/ groups/cid/documents/webcontent/003096-pdf.pdf.
143. Yeguez J, Martinez S, Sands D, Sands L, Hellinger M. Colorectal malignancies in HIV-positive patients. Am Surg. 2003;69:981-7.
144. Grulich A, Li Y, McDonald A, Correll P, Law M, Kaldor J. Rates of non-AIDS defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16:1155-61. (Pubitemid 34533854)
145. Dal Maso L, Franceschi S, Polesel J, et al. Cancer and AIDS Registry Linkage Study. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer. 2003;89:94-100. (Pubitemid 36897942)
146. Cooksley C, Hwang L, Waller D, Ford C. HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. Int J STD AIDS. 1999;10:795-802.
147. Bedimo R, Chen R, Accortt N, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis. 2004;39:1380-4. (Pubitemid 39458526)
148. Bini E, Green B, Poles M. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects. Gut. 2009;58:1129-34.
149. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101:317-24. (Pubitemid 38890835)
150. Cappell M, Yao F, Cho K. Colonic adenocarcinoma associated with the acquired immune deficiency syndrome. Cancer. 1988;62:616-9.
151. Ravalli S, Chabon A, Khan A. Gastrointestinal neoplasia in young HIV antibody-positive patients. Am J Clin Pathol. 1989;91:458-61. (Pubitemid 19097075)
152. Monfardini S, Vaccher E, Pizzocaro G, et al. Unusual malignant tumors in 49 patients with HIV infection. AIDS. 1989;3:449-52. (Pubitemid 19210452)
153. Klugman A, Schaffner J. Colon adenocarcinoma in HIV infection: A case report and review. Am J Gastroenterol. 1994;89:254-6. (Pubitemid 24054189)
154. Demopoulos B, Vamvakas E, Ehrlich J, Demopoulos R. Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human
155. Bini E, Park J, Francois F. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med. 2006;166:1626-31. (Pubitemid 44232372)
156. Chapman C, Aboulafia D, Dezube B, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer. 2009;8:215-9.
157. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute. 2011 (cited 2011 Jun 14). Available at: http://seer.cancer.gov/statfacts/html/colorect.html.
158. Wood N, Feller L. The malignant potential of HIV-associated Kaposi sarcoma. Cancer Cell Int. 2008;8:14.
159. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels A, Maisonneuve P. Smoking and colorectal cancer. JAMA. 2008;300.23:2765-78.
160. Liang P, Chen T, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: Systematic review and meta-analysis. Int J Cancer. 2009;124:2406-15.
161. Recommendations from the 2009 ACG guideline for colorectal cancer screening. ACG Update. 2009 (cited 2011 Jun 6); 18(1): (about 1 screen). Available from: http://www.acoi.org/2010Convention/Cornette- ColorectalCancerScreeningRecommendations.pdf.
162. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee opinion no. 482: colonoscopy and colorectal cancer screening strategies. Obstet Gynecol. 2011;117:766-71.
163. U.S. Preventive Services Task Force (updated 2008 Oct; cited 2011 Jun 6). Screening for colorectal cancer; (about 1 screen). Available from: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm.
164. Rabeneck L, Paszat L, Saskin R, Stukel T. Association between colonoscopy rates and colorectal cancer mortality. Am J Gastroenterol. 2010;105.7:1627-32.
165. Chustecka Z. Screening for colorectal cancer saves lives - no debate, says ACS. Medscape Medical News; 2011 (cited 2011 Jun 7). Available from: http://www.medscape.com/viewarticle/738728.
166. Iqbal S, Browne-McDonald V, Cerulli M. Recent trends for colorectal cancer screening in HIV-infected patients. Dig Dis Sci. 2010;55:761-6.
167. Reinhold J, Moon M, Tenner C, Poles M, Bini E. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol. 2005;100:1805-12. (Pubitemid 41648437)
168. Rosenthal E, Poiree M, Pradier C, et al.; GERMIVIC Joint Study Group. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803-9. (Pubitemid 37000098)
169. Zahng B, Yang B, Tang Z. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22. (Pubitemid 39044345)
170. Nelson R. AIDS patients face higher risk for gastric and esophageal cancers. Medscape Medical News; 2011(cited 2011 Jun 6). Available from: http://www.medscape.com/viewarticle/740694?src=mpnews&spon=7.
171. Newcomb- Fernandez J. Cancer in the HIV-infected population. The Center for AIDS information and Advocacy; 2003 (cited 2011 Jun 7). Available from: http://www.thebody.com/content/art16834.html.
172. Manson J, Mayne S, Clinton S. Vitamin D and prevention of cancer-ready for prime time? N Engl J Med. 2011;364:1385-7.
173. Freund K, Battalia T, Calhoun E, et al. National Cancer Institute Patient Navigation Research Program. Cancer. 2008;113:3391-9.
174. Harrison K, Song R, Zhang X. Life expectancy after HIV diagnosis based on National HIV Surveillance data From 25 states, United States. Journ of Aquir Imm Def Synd. 2010;53:124-30.
175. Aboulafia DM. Immunodeficiency virus-acquired immune deficiency syndrome and cancer: implications for cancer screening in HIV and aging. In: Lee SW, editor. HIV and Aging. New York: Informa Healthcare. 2008;103-30.